In a bid to develop medicines in the neuroscience therapeutic area, Jubilant Life Sciences has entered into drug discovery pact with Finland’s Orion Corporation. The company has entered into the agreement through its Bengaluru-based subsidiary Jubilant Biosys. The research deal is aimed at developing drug that can benefit large population with unmet needs in the pain management area.
Under the royalty-based alliance, Orion will provide royalty to Jubilant and will retain ownership of the compounds developed under the collaboration with exclusive worldwide rights, while Jubilant will offer integrated drug discovery services across synthetic and medicinal chemistry including scale up and pre-clinical facilities.
Jubilant Life Sciences is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1696.65 |
| Dr. Reddys Lab | 1218.30 |
| Cipla | 1226.65 |
| Zydus Lifesciences | 936.00 |
| Lupin | 2339.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: